Search by Drug Name or NDC

    NDC 00078-0709-56 TABRECTA 150 mg/1 Details

    TABRECTA 150 mg/1

    TABRECTA is a ORAL TABLET, FILM COATED in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Novartis Pharmaceuticals Corporation. The primary component is CAPMATINIB HYDROCHLORIDE.

    Product Information

    NDC 00078-0709
    Product ID 0078-0709_761d7399-fb73-455a-88de-c6ec4f13ba2c
    Associated GPIs 21533716200320
    GCN Sequence Number 081014
    GCN Sequence Number Description capmatinib hydrochloride TABLET 150 MG ORAL
    HIC3 V1Q
    HIC3 Description ANTINEOPLASTIC SYSTEMIC ENZYME INHIBITORS
    GCN 48012
    HICL Sequence Number 046519
    HICL Sequence Number Description CAPMATINIB HYDROCHLORIDE
    Brand/Generic Brand
    Proprietary Name TABRECTA
    Proprietary Name Suffix n/a
    Non-Proprietary Name capmatinib
    Product Type HUMAN PRESCRIPTION DRUG
    Dosage Form TABLET, FILM COATED
    Route ORAL
    Active Ingredient Strength 150
    Active Ingredient Units mg/1
    Substance Name CAPMATINIB HYDROCHLORIDE
    Labeler Name Novartis Pharmaceuticals Corporation
    Pharmaceutical Class Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 1A2 Inhibitors [MoA], Kinase Inhibitor [EPC], Mesenchymal Epithelial Transition Inhibitors [MoA], Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA], Multidrug and Toxin Extrusio
    DEA Schedule n/a
    Marketing Category NDA
    Application Number NDA213591
    Listing Certified Through 2025-12-31

    Package

    NDC 00078-0709-56 (00078070956)

    NDC Package Code 0078-0709-56
    Billing NDC 00078070956
    Package 56 TABLET, FILM COATED in 1 BOTTLE (0078-0709-56)
    Marketing Start Date 2020-05-06
    NDC Exclude Flag N
    Pricing Information N/A